Insights

Global Expansion Adragos Pharma has recently expanded its operations in Japan and France, demonstrating a strategic focus on increasing its international manufacturing footprint and serving diverse markets, creating opportunities to upsell advanced manufacturing services and regional supply solutions.

Acquisition Growth The company's recent acquisitions of Fresenius Kabi's site in Norway and Swiss CDMO Baccinex indicate a growth strategy centered on integrating additional sterile and liquid manufacturing capacities, opening avenues for cross-selling comprehensive development and manufacturing packages.

Investment in Capacity Significant investments in new facilities and equipment, including over $13 million to boost output and a $4.28 million upgrade in Leipzig, suggest potential for providing clients with scalable manufacturing solutions, especially for high-volume sterile injectables.

Product Launch Success The recent launch of Isoprenaline in the UK highlights Adragos Pharma’s ability to develop and commercialize specialized drug products, which offers sales opportunities for custom formulation development and market-specific manufacturing services.

Technology Adoption Utilization of advanced production lines and cGMP-compliant facilities signals readiness to meet stringent quality standards, making Adragos Pharma an attractive partner for clients seeking reliable, compliant contract manufacturing solutions for both small molecule and sterile injectable drugs.

Similar companies to Adragos Pharma

Adragos Pharma Tech Stack

Adragos Pharma uses 8 technology products and services including WP Rocket, Wix, Goober, and more. Explore Adragos Pharma's tech stack below.

WP Rocket
Caching
Wix
Content Management System
Goober
Javascript Libraries
Swiper
Javascript Libraries
HubSpot
Marketing Automation
Microsoft
Miscellaneous
RankMath SEO
Web Platform Extensions
Apache HTTP Server
Web Servers

Media & News

Adragos Pharma's Email Address Formats

Adragos Pharma uses at least 1 format(s):

Adragos Pharma Email Formats	Example	Percentage
First.Last@adragos-pharma.com	John.Doe@adragos-pharma.com	49%
First.L@adragos-pharma.com	John.D@adragos-pharma.com	1%
Last@adragos-pharma.com	Doe@adragos-pharma.com	1%
First.Last@adragos-pharma.com	John.Doe@adragos-pharma.com	49%

Frequently Asked Questions

Where is Adragos Pharma's headquarters located?

Adragos Pharma's main headquarters is located at Sonnenstraße 17, Munich, Bavaria 80331, DE. The company has employees across 3 continents, including EuropeAsiaNorth America.

What is Adragos Pharma's official website and social media links?

Adragos Pharma's official website is adragos-pharma.com and has social profiles on LinkedIn Crunchbase.

What is Adragos Pharma's NAICS code?

Adragos Pharma's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Adragos Pharma have currently?

As of October 2025, Adragos Pharma has approximately 501 employees across 3 continents, including EuropeAsiaNorth America. Key team members include Chief Executive Officer: A. R.Chief Commercial Officer (cco): H. Z.Chief Operating Officer: M. R. G.. Explore Adragos Pharma's employee directory with LeadIQ.

What industry does Adragos Pharma belong to?

Adragos Pharma operates in the Pharmaceutical Manufacturing industry.

What technology does Adragos Pharma use?

Adragos Pharma's tech stack includes WP RocketWixGooberSwiperHubSpotMicrosoftRankMath SEOApache HTTP Server.

What is Adragos Pharma's email format?

Adragos Pharma's email format typically follows the pattern of First.Last@adragos-pharma.com. Find more Adragos Pharma email formats with LeadIQ.

When was Adragos Pharma founded?

Adragos Pharma was founded in 2020.

Adragos Pharma

Pharmaceutical ManufacturingGermany501-1000 Employees

We are a globally operating Contract Development and Manufacturing Organisation (CDMO) headquartered in Germany. 

Our sites in Germany, France, Greece and Japan focus on the development and manufacturing of drug products (FDF) in the small molecule segment. Our manufacturing sites cover relevant technologies in sterile liquids, non-sterile liquids, and semi-solids, providing end-to-end services for our large base of (bio)pharma customers. 

Our development site in Greece is a one-stop shop for our partners offering a range of services to take products from inception to MA grant and supply.